Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$6.44M-19.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.1M-10.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$1.52M-60.4%
Cytokinetics logo
CytokineticsCYTK
$72.9M-4.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
5.7%0.0pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$17.23M+140%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemJune 30, 2026December 31, 2025
Prepaid expenses and other current assets48,28542,614
Total current assets668,633527,177
Property and equipment, net2,5751,943
Operating lease right-of-use assets8,3539,807
Other long-term assets10,83411,307
Intangible asset, net14,75015,250
Deferred tax assets190,965198,149
Total assets$896,110$763,633

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's operating lease ROU assets?
Kiniksa Pharmaceuticals International, plc (KNSA) reported operating lease ROU assets of $8.35M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's operating lease ROU assets changed year-over-year?
Kiniksa Pharmaceuticals International, plc's operating lease ROU assets decreased by 18.9% year-over-year, from $10.3M to $8.35M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's operating lease ROU assets?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's operating lease ROU assets has grown at a 8.4% compound annual growth rate (CAGR), from $6.57M to $9.81M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Kiniksa Pharmaceuticals International, plc's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude